Corporate Profile
HCW Biologics is a clinical-stage company advancing the development of transformative immunotherapies to lengthen healthspan by disrupting inflammaging.
HCW Biologics is a clinical-stage company advancing the development of novel immunotherapeutics designed to disrupt the link between chronic, low-grade inflammation and age-related disorders. This field, known as inflammaging, targets the unresolved inflammatory responses and chronic, low-grade inflammation associated with advancing age and believed to be a significant contributing factor to cancer and several chronic conditions, including cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease.
HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index
Data Provided by Refinitiv. Minimum 15 minutes delayed.
| Filing date | Description | Form |
|---|---|---|
Official notification to shareholders of matters to be brought to a vote ("Proxy") |
DEF 14A | |
An annual report to security holders |
ARS | |
Additional proxy soliciting materials - definitive |
DEFA14A | |
Report of unscheduled material events or corporate event |
8-K | |
Annual report which provides a comprehensive overview of the company for the past year |
10-K | |
Notice of Exempt Offering of Securities |
D | |
Report of unscheduled material events or corporate event |
8-K |